A Study to Investigate the Tolerability of Subcutaneous Injections of LY3074828 Compared to Placebo
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs LY900021 (Primary) ; Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 02 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2019 Planned End Date changed from 28 May 2019 to 21 Jun 2019.